Tvardi Therapeutics Inc

69C

Company Profile

  • Business description

    Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.

  • Contact

    3 Sugar Creek Center boulevard
    Suite 525
    Sugar LandTX77478
    USA

    T: +1 713 489-8654

    https://www.tvarditherapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    12

Stocks News & Analysis

stocks

This defensive ASX listed REIT offers a 5% yield

Solid outlook underpinned by rent uplifts and development pipeline.
stocks

Chart of the Week: Anthropic’s IPO range sits below our fair value

Our fair value is above the IPO range, but outcomes could differ widely.
stocks

Taking a look at opportunities in gaming shares as the highly anticipated GTA 6 is released

Several gaming shares are trading at a discount to our fair value.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,832.30100.10-1.12%
CAC 408,146.8369.95-0.85%
DAX 4025,736.24309.13-1.19%
Dow JONES (US)50,198.17561.25-1.11%
FTSE 10010,551.17138.70-1.30%
HKSE22,855.46439.29-1.89%
NASDAQ24,429.88101.500.42%
Nikkei 22559,506.10481.820.82%
NZX 50 Index14,247.2517.04-0.12%
S&P 5007,323.6316.90-0.23%
S&P/ASX 2008,724.1097.70-1.11%
SSE Composite Index3,571.9915.85-0.44%

Market Movers